Funding of Research. The Company shall fund the Research during the Research Period in the total amount of $1,600,000 plus VAT as applicable ("Research Funds"), which shall be paid to Ramot in accordance with the payment schedule set forth in Exhibit F.
Funding of Research. HemoTech shall sponsor research at VCU relating to the Technology. The research shall be sponsored under one or more renewable agreements providing for the payment by HemoTech of [ * ] by December 31, 1995. The terms of such research agreement(s) shall be those contained in the standard research agreement used by VCU, *CONFIDENTIAL TREATMENT REQUESTED 4 except that the research agreement shall provide that inventions made in the course of the research which are included in any claim of a U.S. patent licensed to HemoTech under this agreement will be licensed to HemoTech as part of the Technology licensed under this agreement. If VCU declines to enter into agreement(s) containing such terms, HemoTech shall not be obligated by this agreement to sponsor such research.
Funding of Research. The Company shall fund the Research during the Research Period in the total amount of237,630NIS, which shall be paid to Ramot in accordance with the payment schedule set forth in Exhibit F. Payment shall be made against valid tax invoice. For the avoidance of doubt, all payments payable to Ramot pursuant to this Section should be net of any deductions or tax withholding, if applicable, which shall be borne by Sponsor.
Funding of Research. The Company shall fund the Research during the Research Period in the total amount of $100,000 (one hundred thousand USD) 'which will be exempt from additional VAT surcharge provided that the money is transferred directly from the USA to Ariel’s Israeli bank account ("Research Funds"), which shall be paid to Ariel upon the Effective Date ("Research Financing") and be utilized per the Research Plan.
Funding of Research. The Company shall fund the Research during the Research Period in the total amount of US$ 1,177,200 (one million, one hundred and seventy-seven thousand and two hundred US Dollars) plus value added tax to the extent required by applicable law, which shall be paid to Ramot, as follows: (“First Instalment”) (“Second Instalment”) (“Third Instalment”) (“Fourth Instalment”) The actual spending of the budget might vary between the different cost items, at the Principal Investigator’s sole discretion, however the total budget will not be changed. For the avoidance of doubt, all payments payable to Ramot pursuant to this Section should be net of any deductions or tax withholding, if applicable, which shall be borne by the Company.
Funding of Research. Institution represents, warrants and covenants to Company that no third party has funded or will fund any part of the Research other than the United States government or an agency thereof (the “US Government”) or the Commonwealth of Pennsylvania. In the event that the US Government has funded any portion of any research program that Company also funds pursuant to this Agreement, Institution agrees to promptly notify Company of this fact and provide additional details as reasonably requested by the Company. Institution covenants and agrees, during the Term, not to seek US Government funding for any Research to be performed under this Agreement without the prior written consent of Company, such consent not to be unreasonably delayed or withheld.
Funding of Research. Institution represents, warrants and covenants to Company that no third party, other than the United States government or an agency thereof (the “US Government”) or the Commonwealth of Pennsylvania, has funded or will fund any part of the Research. In the event that the US Government has funded any portion of any research program that Company also funds, at any time, pursuant to this Agreement, Institution agrees to promptly notify Company of this fact and provide additional details as reasonably requested by the Company. Institution covenants and agrees, during the Term, not to seek US Government funding for any research within the scope of that which is funded by the Company under any then-current Project Plan without the prior written consent of Company, such consent not to be unreasonably delayed or withheld. Institution shall be free to seek direct US Government funding (other than a sub-award) for research in the field of HBV but outside the scope of that which is funded by the Company under any then-current Project Plan (“Other Research”) provided that: (i) at least [***] prior to the submission of any application or similar document to be submitted in support of Institution’s efforts to seek such funding (each a “Grant Application”), Institution shall provide Company with substantially complete copies or experimental plans, whether final or draft, of each Grant Application; (ii) Institution hereby agrees to remove from any Grant Application any information Company and Institution jointly determine is Confidential Information (as defined below); and (iii) in the event that Company, after review of a Grant Application, determines that it wishes to fund such Other Research on the same financial terms as would be provided under the Grant Application if funded, Institution shall not submit such Grant Application to the US Government and shall instead, within [***] from submission of the Grant Application to Company, enter into a separate agreement with Company for the funding of such Other Research on terms not less favorable to the Company than those contained herein with respect to the Research. Upon failure of the parties to enter into a separate agreement in the specified timeframe, Institution shall be permitted to file its grant application with the US Government.
Funding of Research. As consideration to deCODE for the research and development activities undertaken by deCODE pursuant to this Agreement:
Funding of Research. 4.1. OSI Staffing of Anaderm-Sponsored Research. OSI agrees to use its reasonable best efforts to employ and allocate at least the number of full-time research scientists to conduct its drug discovery efforts under the Research Program during each of the three years of the Contract Period, as set forth in Appendix A. Thus, OSI agrees to use its reasonable best efforts to employ and allocate an annual average of at least ** full-time research scientists to conduct its drug discovery efforts under the Research Program during the first year of the ---------- ** This portion has been redacted pursuant to a request for confidential treatment.
Funding of Research except that the research agreement shall provide that inventions made in the course of the research which are included in any claim of a U.S. patent licensed to HemoTech under this agreement will be licensed to HemoTech as part of the Technology licensed under this agreement. If VCU declines to enter into agreement(s) containing such terms, HemoTech shall not be obligated by this agreement to sponsor such research.
